What's in Pontificia Universidad Catolica de Chile's pipeline?

Pontificia Universidad Catolica de Chile has 32 drugs in our index: 16 marketed, 0 filed, 3 in Phase 3, 7 in Phase 2, 6 in Phase 1.

Which companies overlap with Pontificia Universidad Catolica de Chile's portfolio?

Top competitors by shared drug class: Federal University of São Paulo, Keimyung University Dongsan Medical Center, Bozyaka Training and Research Hospital, Express Specialty Pharmacy, Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pontificia-universidad-catolica-de-chile.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Pontificia Universidad Catolica de Chile — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pontificia Universidad Catolica de Chile pipeline: 16 marketed, 0 filed, 3 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

16 marketed 0 filed 3 Phase 3 7 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Hepatitis B recombinant vaccine	Hepatitis B recombinant vaccine	marketed	Recombinant vaccine	Hepatitis B surface antigen (HBsAg)	Immunology
N-acetylcysteine 500 mg	N-acetylcysteine 500 mg	marketed
H-Bupivacaine	H-Bupivacaine	marketed
Levobupivacaine 25 mL	Levobupivacaine 25 mL	marketed
Water (Placebo)	Water (Placebo)	marketed
Post-operative	Post-operative	marketed	Opioid	Mu opioid receptor	Pain management
N-acetylcysteine 1000 mg	N-acetylcysteine 1000 mg	marketed
Artificial Saliva	Artificial Saliva	marketed
Methadone Injectable Product	Methadone Injectable Product	marketed
Levobupivacaine 10 mL	Levobupivacaine 10 mL	marketed
Cyclopentolate+tropicamide+phenylephrine	Cyclopentolate+tropicamide+phenylephrine	marketed	Anticholinergic + sympathomimetic combination	Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor	Ophthalmology
Levobupivacaine without epinephrine	Levobupivacaine without epinephrine	marketed	Local anesthetic (amide)	Voltage-gated sodium channels	Anesthesia

Therapeutic area mix

Ophthalmology · 3
Anesthesia · 2
Pain management · 2
Immunology · 1
Dermatology · 1
Other · 1
Urology · 1
Gastroenterology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Federal University of São Paulo · 2 shared drug classes
Keimyung University Dongsan Medical Center · 2 shared drug classes
Bozyaka Training and Research Hospital · 2 shared drug classes
Express Specialty Pharmacy · 2 shared drug classes
Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias · 2 shared drug classes
Kasr El Aini Hospital · 2 shared drug classes
Beijing Tiantan Hospital · 2 shared drug classes
Massachusetts General Hospital · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Pontificia Universidad Catolica de Chile:

Cite this brief

Drug Landscape (2026). Pontificia Universidad Catolica de Chile — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pontificia-universidad-catolica-de-chile. Accessed 2026-05-17.